Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains of Staphylococcus aureus
- 1 February 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (2) , 335-340
- https://doi.org/10.1128/aac.43.2.335
Abstract
NorA is a membrane-associated multidrug efflux protein that can decrease susceptibility to fluoroquinolones in Staphylococcus aureus. To determine the effect of NorA inhibition on the pharmacodynamics of fluoroquinolones, we evaluated the activities of levofloxacin, ciprofloxacin, and norfloxacin with and without various NorA inhibitors against three genetically related strains of S. aureus (SA 1199, the wild-type; SA 1199B, a NorA hyperproducer with a grlA mutation; and SA 1199-3, a strain that inducibly hyperproduces NorA) using susceptibility testing, time-kill curves, and postantibiotic effect (PAE) methods. Levofloxacin had the most potent activity against all three strains and was minimally affected by addition of NorA inhibitors. In contrast, reserpine, omeprazole, and lansoprazole produced 4-fold decreases in ciprofloxacin and norfloxacin MICs and MBCs for SA 1199 and 4- to 16-fold decreases for both SA 1199B and SA 1199-3. In time-kill experiments reserpine, omeprazole, or lansoprazole increased levofloxacin activity against SA 1199-3 alone by 2 log10CFU/ml and increased norfloxacin and ciprofloxacin activities against all three strains by 0.5 to 4 log10 CFU/ml. Reserpine and omeprazole increased norfloxacin PAEs on SA 1199, SA 1199B, and SA 1199-3 from 0.9, 0.6, and 0.2 h to 2.5 to 4.5, 1.1 to 1.3, and 0.4 to 1.1 h, respectively; similar effects were observed with ciprofloxacin. Reserpine and omeprazole increased the levofloxacin PAE only on SA 1199B (from 1.6 to 5.0 and 3.1 h, respectively). In conclusion, the NorA inhibitors dramatically improved the activities of the more hydrophilic fluoroquinolones (norfloxacin and ciprofloxacin). These compounds may restore the activities of these fluoroquinolones against resistant strains of S. aureus or may potentially enhance their activities against sensitive strains.Keywords
This publication has 28 references indexed in Scilit:
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisersEuropean Journal Of Cancer, 1996
- Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignanciesEuropean Journal Of Cancer, 1996
- Pharmacological considerations in the modulation of multidrug resistanceEuropean Journal Of Cancer, 1996
- Steroid Transport, Accumulation, and Antagonism of P-Glycoprotein in Multidrug-Resistant CellsBiochemistry, 1996
- Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and ChinaJournal of Medical Microbiology, 1995
- Mechanisms of quinolone resistanceInfection, 1994
- Efflux-mediated fluoroquinolone resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1993
- Mechanisms of Resistance to QuinolonesDrugs, 1993
- Mechanisms of Fluoroquinolone Resistance in Staphylococcus aureusThe Journal of Infectious Diseases, 1991